Invivyd, Inc.
IVVD- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001832038
No open-market purchases or sales by Invivyd, Inc. insiders were filed in the last 90 days; 125 institutions reported holding it in 13F filings for Q2 2026, worth $203.1M in total; Maverick Capital is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 17, 2026, 2:22 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $52.5M (98.2% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Feb 3, 2025 | Mar 25, 2024 | Mar 23, 2023 | Mar 30, 2022 |
| Revenue | $53.4M | $25.4M | – | – | – |
| Operating expenses | $109.0M | $202.3M | $212.8M | $248.0M | $226.9M |
| Research and development | $38.3M | $137.3M | $158.7M | $179.2M | $182.9M |
| Selling, general and administrative | $66.9M | $63.4M | $49.1M | $47.0M | $36.5M |
| Operating income | -$55.6M | -$176.9M | -$212.8M | -$248.0M | -$226.9M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$52.5M | -$169.9M | -$198.6M | -$241.3M | -$226.8M |
| EPS, basic | $-0.30 | $-1.43 | $-1.81 | $-2.23 | – |
| EPS, diluted | $-0.30 | $-1.43 | $-1.81 | $-2.23 | – |
| Weighted shares, basic | 172.2M | 118.6M | 109.5M | 108.3M | 42.6M |
| Weighted shares, diluted | 172.2M | 118.6M | 109.5M | 108.3M | – |
| Margins and growth | |||||
| Operating margin | -104.0% | -696.8% | – | – | – |
| Net margin | -98.2% | -669.4% | – | – | – |
| Revenue growth, year over year | +110.5% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Feb 3, 2025 | Mar 25, 2024 | Mar 23, 2023 | Mar 30, 2022 |
| Cash and equivalents | $226.7M | $69.3M | $200.6M | $92.1M | $542.2M |
| Accounts receivable | $13.9M | $10.9M | – | – | – |
| Inventory | – | $25.9M | – | – | – |
| Total current assets | $247.5M | $100.7M | $224.9M | $376.9M | $616.7M |
| Property, plant and equipment | $1.36M | $1.51M | $1.90M | $2.28M | $83.0K |
| Total assets | $276.9M | $129.5M | $229.2M | $383.2M | $620.1M |
| Accounts payable | $13.7M | $10.4M | $7.95M | $1.52M | $5.78M |
| Total current liabilities | $34.2M | $62.0M | $50.3M | $25.0M | $62.1M |
| Total liabilities | $35.3M | $62.0M | $51.7M | $27.2M | $62.1M |
| Shareholders' equity | $241.5M | $67.5M | $177.5M | $356.0M | $558.0M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Feb 3, 2025 | Mar 25, 2024 | Mar 23, 2023 | Mar 30, 2022 |
| Operating cash flow | -$58.1M | -$170.5M | -$173.2M | -$220.0M | -$184.7M |
| Capital expenditures | $155.0K | $140.0K | $615.0K | $1.71M | $84.0K |
| Free cash flow | -$58.3M | -$170.6M | -$173.8M | -$221.7M | -$184.8M |
| Stock-based compensation | $11.6M | $19.8M | $18.7M | $21.6M | $17.8M |
| Share buybacks | – | $0 | $1.00K | $4.00K | $0 |
| Investing cash flow | -$155.0K | -$140.0K | $280.7M | -$230.7M | -$50.7M |
| Financing cash flow | $215.6M | $39.3M | $1.04M | $506.0K | $662.7M |
| Net change in cash | $157.3M | -$131.3M | $108.6M | -$450.1M | $427.2M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 21.8% | 78.0% | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 29, 2026 | 295.6M | +26.8% | SEC |
| Jul 30, 2026 | 294.8M | +145.3% | SEC |
| Apr 30, 2026 | 294.6M | +145.6% | SEC |
| Feb 26, 2026 | 282.6M | +135.6% | SEC |
| Oct 30, 2025 | 233.1M | +94.9% | SEC |
| Aug 1, 2025 | 120.1M | +0.6% | SEC |
| May 1, 2025 | 120.0M | +0.5% | SEC |
| Mar 11, 2025 | 120.0M | +0.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.